These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1959847)

  • 1. Colchicine clearance is impaired in alcoholic cirrhosis.
    Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
    Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects.
    Mazoit JX; Sandouk P; Zetlaoui P; Scherrmann JM
    Anesth Analg; 1987 Apr; 66(4):293-8. PubMed ID: 3565791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.
    Campillo B; Sherman E; Richardet JP; Bories PN
    Eur J Clin Nutr; 2001 Nov; 55(11):980-8. PubMed ID: 11641747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sufentanil pharmacokinetics in patients with cirrhosis.
    Chauvin M; Ferrier C; Haberer JP; Spielvogel C; Lebrault C; Levron JC; Duvaldestin P
    Anesth Analg; 1989 Jan; 68(1):1-4. PubMed ID: 2521279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal.
    Henriksen JH; Holst JJ; Møller S; Brinch K; Bendtsen F
    Hepatology; 1999 Jun; 29(6):1818-24. PubMed ID: 10347125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
    Morgan MY; Stambuk D
    Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis.
    D'Honneur G; Khalil M; Dominique C; Haberer JP; Kleef UW; Duvaldestin P
    Anesth Analg; 1993 Dec; 77(6):1203-6. PubMed ID: 8250313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
    Hamberg O; Vilstrup H
    Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting plasma somatostatin in alcoholic liver disease.
    Kelbaek H; Tronier B; Bahnsen M; Munkgaard S; Pedersen H
    Scand J Clin Lab Invest; 1983 Nov; 43(7):597-601. PubMed ID: 6140748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
    Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
    Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
    Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
    Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.